Abstract
Background: The 2020 pandemic of SARS-CoV-2 causing COVID-19 disease is an unprecedented global emergency. COVID-19 appears to be a disease with an early phase where the virus replicates, coinciding with the first presentation of symptoms, followed by a later ‘inflammatory’ phase which results in severe disease in some individuals. It is known from other rapidly progressive infections such as sepsis and influenza that early treatment with antimicrobials is associated with a better outcome. The hypothesis is that this holds for COVID-19 and that early antiviral treatment may prevent progression to the later phase of the disease.
Methods: Trial design: Phase IIA randomised, double-blind, 2 × 2 design, placebo-controlled, interventional trial.
Randomisation: Participants will be randomised 1:1 by stratification, with the following factors: gender, obesity, symptomatic or asymptomatic, current smoking status presence or absence of comorbidity, and if the participant has or has not been vaccinated.
Blinding: Participants and investigators will both be blinded to treatment allocation (double-blind).
Discussion: We propose to conduct a proof-of-principle placebo-controlled clinical trial of favipiravir plus or minus nitazoxanide in health workers, their household members and patients treated at the Mexican Social Security Institute (IMSS) facilities. Participants with or without symptomatic COVID-19 or who tested positive will be assigned to receive favipiravir plus nitazoxanide or favipiravir plus nitazoxanide placebo. The primary outcome will be the difference in the amount of virus (‘viral load’) in the upper respiratory tract after 5 days of therapy. Secondary outcomes will include hospitalization, major morbidity and mortality, pharmacokinetics, and impact of antiviral therapy on viral genetic mutation rate. If favipiravir with nitazoxanide demonstrates important antiviral effects without significant toxicity, there will be a strong case for a larger trial in people at high risk of hospitalization or intensive care admission, for example older patients and/or those with comorbidities and with early disease.
Trial registration: ClinicalTrials.gov NCT04918927 . Registered on June 9, 2021.
Keywords: 2×2 design; Antivirals; COVID-19; Combination therapy; Early treatment; Favipiravir; Nitazoxanide; Placebo-controlled trial; Protocol; Randomised controlled trial.
【저자키워드】 COVID-19, protocol, antivirals, Favipiravir, combination therapy, Randomised controlled trial., early treatment, placebo-controlled trial, nitazoxanide, 2×2 design, 【초록키워드】 Stratification, SARS-CoV-2, antiviral therapy, randomised controlled trial, pandemic, therapy, Mutation, Trial, randomised, intensive care, Hospitalization, Influenza, obesity, Genetic, Infection, Comorbidities, Favipiravir, Comorbidity, Gender, Toxicity, combination therapy, pharmacokinetics, Sepsis, Antiviral treatment, progression, outcome, virus, Symptoms, antimicrobial, Antiviral effect, COVID-19 disease, older patient, Health, Asymptomatic, Viral load, symptomatic, early treatment, placebo-controlled trial, Controlled trial, Antimicrobials, nitazoxanide, Placebo, morbidity and mortality, security, smoking status, disease, mutation rate, Admission, upper respiratory tract, placebo-controlled, Hypothesis, symptomatic COVID-19, Inflammatory, phase IIa, severe disease, phase, double-blind, high risk, genetic mutation, followed by, in some, early disease, presence or absence, Social Security, Primary outcome, Secondary outcomes, early phase, investigators, placebo-controlled clinical trial, investigator, participant, treatment allocation, positive, later phase, replicates, Prevent, secondary, tested, example, include, the disease, appear, absence, individuals, assigned, receive, 1:1, blinded to treatment, patients treated, those with comorbidity, 【제목키워드】 therapy, Randomized, Health, double-blind, patients treated,